ADC ASSETS

SDV2102: First-in-class GeminiMab DAR1 ADC targeting PSMA for the treatment of metastatic castration resistant prostate cancer (mCRPC). Anticipating FIH trials in 2025.

SDV2103: Best-in-class GeminiMab DAR2 Integratecan™ ADC targeting TROP-2 for the treatment of metastatic breast cancer. Anticipating FIH trials in 2026.

Syndivia's GeminiMab™ DAR1 approach is being applied to a range of promising targets, including Nectin-4, TF, FRα, ROR1, EGFR, c-MET, and B7-H3.

PARTNERSHIPS

2017: Out-licensing agreement established with Inatherys, limited to one target (CD71). The ADC is currently undergoing phase I/IIa clinical trial (NCT03957915).

2022: Auricula Biosciences co-founded with TVM and Eli Lilly to develop Syndivia’s SDV1001 clinical candidate targeting K-Ras malignancies. Financed through phase I/IIa clinical trial.